目的 探討蒲地藍消炎口服液聯(lián)合羅紅霉素治療小兒急性化膿性扁桃體炎的臨床療效。方法 選取2017年9月-2019年9月在鄭州大學附屬兒童醫(yī)院兒科住院治療的急性化膿性扁桃體炎患兒116例為研究對象，隨機分為對照組和治療組，每組各58例。對照組飯前1 h或飯后4 h口服羅紅霉素分散片，2.5 mg/（kg·次），2次/d。治療組在對照組治療基礎上口服蒲地藍消炎口服液，10 mL/次，3次/d。兩組患兒均連續(xù)治療7 d。觀察兩組患兒的臨床療效；記錄患兒臨床癥狀消失時間；比較治療前后患兒血清白細胞介素6（IL-6）、IL-8、IL-1β、IL-18、腫瘤壞死因子α（TNF-α）、C反應蛋白（CRP）水平。結果 治療后，治療組總有效率96.55%，顯著高于對照組81.03%（P<0.05）。治療后，治療組患兒咽痛消失時間、膿點消失時間、退熱時間、扁桃體恢復正常時間均顯著短于對照組（P<0.05）。治療后，治療組患兒血清IL-6、IL-1β、IL-18、TNF-α、CRP水平均較治療前顯著降低（P<0.05）；治療后，治療組這些炎性因子水平顯著低于對照組（P<0.05）。治療組不良反應發(fā)生率是6.89%，顯著低于對照組的17.24%（P<0.05）。結論 蒲地藍消炎口服液聯(lián)合羅紅霉素治療小兒急性化膿性扁桃體炎具有較好的臨床療效，可有效縮短臨床癥狀時間，降低炎性因子水平，具有一定的臨床推廣應用價值。

Objective To investigate the curative effect of Pudilan Xiaoyan Oral Liquid combined with roxithromycin in treatment of children with acute suppurative tonsillitis. Methods A total of 116 children with acute suppurative tonsillitis who were hospitalized in Children's Hospital Affiliated to Zhengzhou University from September 2017 to September 2019 were selected as the research objects. The patients were randomly divided into control group and treatment group with 58 cases in each group. Children in the control group were po administered with Roxithromycin Dispersible Tablets 1 hour before or 4 hours after meals, 2.5 mg/kg, twice daily. Children in the treatment group were po administered with Pudilan Xiaoyan Oral Liquid on the basis of treatment in the control group, 10 mL/time, three times daily. Both groups were treated continuously for 7 days. The clinical efficacy of the two groups was observed, and the disappearance time of clinical symptoms was recorded. The serum levels of interleukin 6 (IL-6), IL-8, IL-1, IL-18, tumor necrosis factor α (TNF-α), and C-reactive protein (CRP) were compared before and after treatment. Results After treatment, the total effective rate of the treatment group was 96.55%, significantly higher than that of the control group (81.03%, P<0.05). After treatment, the disappearance time of pharyngeal pain, pus point, the time for antipyretic fever and the restoration time of tonsils in the treatment group were significantly shorter than those in the control group (P<0.05). After treatment, the serum levels of IL-6, IL-1, IL-18, TNF-α, and CRP in the treatment group were significantly lower than those before treatment (P<0.05). After treatment, the level of these inflammatory factors in the treatment group was significantly lower than that in the control group (P<0.05). The incidence of adverse reactions in the treatment group was 6.89%, significantly lower than that in the control group (17.24%, P<0.05). Conclusion Pudilan Xiaoyan Oral Liquid combined with roxithromycin has good clinical effect in treatment of children with acute suppurative tonsillitis, and can effectively shorten the time of clinical symptoms, and can reduce the level of inflammatory factors, which has certain clinical application value.

R987

河南省醫(yī)學科技攻關項目（2018020682）